Lisa Juby

The public hearing focused on the Commissioner’s National Priority Voucher pilot program. Key discussion topics included the program's eligibility criteria, voucher selection processes, sponsor responsibilities, FDA review procedures, and program implementation. Presentations and stakeholder feedback emphasized the importance of streamlined, efficient, and predictable review timelines for innovative therapies addressing serious or rare diseases, alongside requests for clear communication channels and structured engagement opportunities. Participants also discussed the role of data and patient perspectives in informing regulatory decisions.

The committee convened to review surveillance and epidemiology data regarding SARS-CoV-2, including the genetic and antigenic characteristics of recent virus isolates. Key discussion topics included the effectiveness of current COVID-19 vaccines and the evaluation of candidate vaccines for the 2026-2027 formula. The committee deliberated on recommendations for the composition of the upcoming COVID-19 vaccine formula for use in the United States, including the potential selection of a JN1 lineage or other variants.

The meeting focused on the implementation of the FDA's Plausible Mechanism Framework for individualized medicine. Key discussion topics included the scientific and regulatory strategies for developing targeted therapies for ultra-rare diseases, such as genetic treatments and oligonucleotide therapies. The session provided an update on the treatment of a patient with a urea cycle disorder and outlined the five foundational aspects of the framework: identifying disease abnormalities, developing targeted therapies, leveraging natural disease history, confirming target engagement, and demonstrating improvements in clinical outcomes. The agency discussed its commitment to streamlining the review process for these transformational treatments while maintaining rigorous safety and efficacy standards.

The committee meeting focused on discussing the dosimetry data requirements for positron emission tomography (PET) drugs, specifically evaluating the sufficiency of available animal or human study data to support initial clinical study applications. The FDA proposed a leveraging approach to streamline radiation safety assessments by establishing radioactivity thresholds. The committee heard perspectives from an industry representative and a translational laboratory researcher regarding regulatory challenges and scientific considerations for these imaging agents.

The committee discussed the efficacy of oral phenylephrine as a nasal decongestant, specifically reviewing new data that has become available since the committee last examined the issue in 2007. The discussion also covered the potential safety and efficacy of doses higher than those outlined in the current monograph. The session included introductory remarks from FDA officials, a review of the regulatory standards for effectiveness under the monograph, and information regarding conflict of interest compliance for committee members.